CA2310926C - A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease - Google Patents
A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease Download PDFInfo
- Publication number
- CA2310926C CA2310926C CA002310926A CA2310926A CA2310926C CA 2310926 C CA2310926 C CA 2310926C CA 002310926 A CA002310926 A CA 002310926A CA 2310926 A CA2310926 A CA 2310926A CA 2310926 C CA2310926 C CA 2310926C
- Authority
- CA
- Canada
- Prior art keywords
- day
- galantamine
- treatment
- weeks
- dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19425900P | 2000-04-03 | 2000-04-03 | |
US60/194,259 | 2000-04-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2310926A1 CA2310926A1 (en) | 2000-10-04 |
CA2310926C true CA2310926C (en) | 2002-10-15 |
Family
ID=22716898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002310926A Expired - Lifetime CA2310926C (en) | 2000-04-03 | 2000-06-27 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1272192A2 (es) |
JP (1) | JP2003528913A (es) |
KR (1) | KR20020086911A (es) |
CN (1) | CN1430514A (es) |
AU (2) | AU6584401A (es) |
BG (1) | BG107093A (es) |
BR (1) | BR0109770A (es) |
CA (1) | CA2310926C (es) |
CZ (1) | CZ20023543A3 (es) |
EE (1) | EE200200554A (es) |
HR (1) | HRP20020778A2 (es) |
HU (1) | HUP0300566A3 (es) |
IL (1) | IL152061A0 (es) |
MX (1) | MXPA02009777A (es) |
NO (1) | NO20024746L (es) |
PL (1) | PL361272A1 (es) |
RU (1) | RU2002129298A (es) |
SK (1) | SK15422002A3 (es) |
WO (1) | WO2001074339A2 (es) |
ZA (1) | ZA200207935B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
BRPI0412919A (pt) | 2003-07-25 | 2006-09-26 | Hoffmann La Roche | combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos |
DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
MX2010010460A (es) | 2008-03-27 | 2010-12-15 | Chase Pharmaceuticals Corp | Uso y composicion para tratar la demencia. |
WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
BG66818B1 (bg) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
EP3297632A4 (en) * | 2015-05-18 | 2019-01-16 | Synaptec Development LLC | GALANTAMINE ELIMINATION OF AMYLOIDSS |
WO2023036105A1 (zh) * | 2021-09-09 | 2023-03-16 | 上海日馨医药科技股份有限公司 | 治疗神经退行性疾病的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
AU1738800A (en) | 1998-11-23 | 2000-06-13 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
HUP0104778A3 (en) * | 1998-12-24 | 2004-05-28 | Janssen Pharmaceutica Nv | Controlled release galantamine composition |
CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/en not_active Expired - Lifetime
-
2001
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/en not_active Application Discontinuation
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Application Discontinuation
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 EP EP01943200A patent/EP1272192A2/en not_active Withdrawn
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-09-26 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL361272A1 (en) | 2004-10-04 |
EP1272192A2 (en) | 2003-01-08 |
BG107093A (bg) | 2003-06-30 |
AU2001265844B2 (en) | 2005-04-14 |
MXPA02009777A (es) | 2003-03-27 |
HUP0300566A3 (en) | 2004-10-28 |
AU6584401A (en) | 2001-10-15 |
KR20020086911A (ko) | 2002-11-20 |
BR0109770A (pt) | 2003-02-04 |
NO20024746D0 (no) | 2002-10-02 |
CZ20023543A3 (cs) | 2003-03-12 |
CA2310926A1 (en) | 2000-10-04 |
JP2003528913A (ja) | 2003-09-30 |
ZA200207935B (en) | 2004-01-30 |
EE200200554A (et) | 2004-04-15 |
RU2002129298A (ru) | 2004-03-27 |
HRP20020778A2 (en) | 2004-04-30 |
IL152061A0 (en) | 2003-05-29 |
NO20024746L (no) | 2002-11-28 |
SK15422002A3 (sk) | 2003-04-01 |
WO2001074339A2 (en) | 2001-10-11 |
CN1430514A (zh) | 2003-07-16 |
HUP0300566A2 (hu) | 2003-06-28 |
WO2001074339A3 (en) | 2002-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU621035B2 (en) | The administration of monoamine acridines in cholinergic neuronal deficit states | |
Granacher et al. | Physostigmine: Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs | |
JP4097285B2 (ja) | 種々の頑固な疾患の治療のための医薬の製造に有用な組成物 | |
CA2310950C (en) | An efficacious dosage regiment of galantamine that reduces side effects | |
US7943632B2 (en) | High potency dopaminergic treatment of neurological impairment associated with brain injury | |
CA2310926C (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
KR20220012281A (ko) | 브루톤 티로신 키나제 저해제를 이용하여 만성 자발성 두드러기를 치료하는 방법 | |
AU2001265844A1 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
US20060172993A1 (en) | Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease | |
US12023315B2 (en) | Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis | |
Stanaland | Treatment of patients with chronic idiopathic urticaria | |
WO2015153263A1 (en) | Compositions and methods to treat addiction | |
US20050203105A1 (en) | Composition and method for controlling alcohol-induced facial flushing in susceptible humans | |
JP2005306882A (ja) | 感情的不安定の治療のための医薬の製造に有用な組成物 | |
Panas et al. | Belladonna alkaloids and phenobarbital use in the treatment of irritable bowel syndrome: a review | |
WO2020014072A1 (en) | Neostigmine pharmaceutical combination for treating myasthenia gravis | |
RU2818678C2 (ru) | Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона | |
US11752141B2 (en) | Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis | |
Flowers et al. | Antihistamines. | |
JP4372723B2 (ja) | 慢性疼痛の治療のための医薬の製造に有用な組成物 | |
CA2310990A1 (en) | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease | |
de Haen | Annual Review of New Drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20200629 |